Evolocumab Reduces LDL in Patients With Diabetes

diabetes-cholesterol.gif" height="300" width="300" />

 

Evolocumab (Repatha, Amgen) reduced low-density lipoprotein (LDL) cholesterol levels by 60% in patients with type 2 diabetes, according to a new analysis of individual patient data from three 12-week, randomized controlled trials comparing the efficacy of evolocumab with ezetimibe (Zetia, Merck) and placebo in adults with and without type 2 diabetes (Lancet Diabetes Endocrinol
2016 Feb 8. [Epub ahead of print]).

 

After